—In Europe, patients with Philadelphia chromosome-positive CML generally have better rates of survival than similar patients in the U.S. These investigators at MD Anderson Cancer Center tried to ...

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found. Treatment with ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

(RTTNews) - Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia ...